ELZONRIS leverages first-mover status, global approvals, strong clinical adoption and expansion into CD123-positive cancers, backed by pricing and competitive analysis.Dublin, Oct. 09, 2026 (GLOBE ...
A 69-year-old man developed severe paroxysmal cold hemoglobinuria following shingles and COVID-19, in what researchers report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results